Vitamin D suppresses leptin stimulation of cancer growth through microRNA

Cancer Research

Volumn 74, Issue 21, 2014, Pages 6194-6204

  Kasiappan, Ravi ^a   Sun, Yuefeng ^a   Lungchukiet, Panida ^a   Quarni, Waise ^a   Zhang, Xiaohong ^a,b   Bai, Wenlong ^a,b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; ESTROGEN RECEPTOR ALPHA; LEPTIN; MESSENGER RNA; MICRORNA; MICRORNA 498; SEOCALCITOL; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG; ESTROGEN RECEPTOR ALPHA, HUMAN; MIRN498 MICRORNA, HUMAN; TELOMERASE; TERT PROTEIN, HUMAN; VITAMIN D;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER PREVENTION; CANCER RISK; CELL GROWTH; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION; GENE INDUCTION; HUMAN; HUMAN CELL; LIPID DIET; MOUSE; NONHUMAN; OBESITY; OVARY TUMOR; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RISK REDUCTION; TUMOR GROWTH; ANIMAL; BIOSYNTHESIS; BREAST NEOPLASMS; CELL DIVISION; CELL PROLIFERATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; OVARIAN NEOPLASMS; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; CELL PROLIFERATION; DIET, HIGH-FAT; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEPTIN; MICE; MICRORNAS; OVARIAN NEOPLASMS; TELOMERASE; VITAMIN D;

EID: 84910002431     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-1702     Document Type: Article

References (50)

1. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625-38.
2. Vendrell J, Broch M, Vilarrasa N, Molina A, Gomez JM, Gutierrez C, et al., Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity, Obes Res, 2004, 12, 962-71.
3. Owecki M, Nikisch E, Miczke A, Pupek-Musialik D, Sowinski J. Leptin, soluble leptin receptors, free leptin index, and their relationship with insulin resistance and BMI: high normal BMI is the threshold for serum leptin increase in humans. Horm Metab Res 2010;42:585-9.
4. Tessitore L, Vizio B, Pesola D, Cecchini F, Mussa A, Argiles JM, et al. Adipocyte expression and circulating levels of lep tin increase in both gynaecological and breast cancer patients. Int J Oncol 2004;24: 1529-35.
5. Uddin S, Bu R, Ahmed M, Abubaker J, Al-Dayel F, Bavi P, et al. Overexpression of lepti n receptor predicts an unfavorable outcome in Middle Eastern ovarian cancer. Mol Cancer 2009;8:74.
6. Kaga T, Inui A, Okita M, Asakawa A, Ueno N, Kasuga M, et al. Modest overexpressio n of neuropeptide Y in the brain leads to obesity after high-sucrose feeding. Diabetes 2001;50:1206-10.
7. Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D, et al. Cancer incid ence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ 2007;335:1134.
8. Garofalo C, Surmacz E. Leptin and cancer. J Cell Physiol 2006;207: 12-22.
9. Lang K, Ratke J. Leptin and Adiponectin: new players in the field of tumor cell and leukocyte migration. Cell Commun Signal 2009;7:27.
10. Catalano S, Marsico S, G iordano C, Mauro L, Rizza P, Panno ML, et al. Leptin enhances, via AP-1, expression of aromatase in the MCF-7 cell line. J Biol Chem 2003;278:28668-76.
11. Pino AM, Rodriguez JM, Rios S, Astudillo P, Leiva L, Seitz G, et al. Aromatase activity of human mesenchymal stem cells is stimulated by early differentiation, vitamin D and leptin. J Endocrinol 2006;191: 715-25.
12. B inai NA, Damert A, Carra G, Steckelbroeck S, Lower J, Lower R, et al. Expression of estrogen receptor alpha increases leptin-induced STAT3 activity in breast cancer cells. Int J Cancer 2010;127:55-66.
13. Catalano S, Mauro L, Marsico S, Giordano C, Rizza P, Rago V, et al. Leptin induces, via ERK1/ERK2 signal, functional activation of estrogen receptor alpha in MCF-7 cells. J Biol Chem 2004;27 9:19908-15.
14. Choi JH, Lee KT, Leung PC. Estrogen receptor alpha pathway is involved in leptin-induced ovarian cancer cell growth. Carcinogenesis 2011;32:589-96.
15. Bertone ER, Rosner BA, Hunter DJ, Stampfer MJ, Speizer FE, Colditz GA, et al. Dietary fat intake and ovarian cancer in a cohort of US women. Am J Epidemiol 2002;156:22-31.
16. Verkasalo PK, Thomas HV, Appleby PN, Davey GK, Key TJ. Circulating levels of sex hormones and their relation to risk factors for breast cancer: a cross-sectional study in 1092 pre-and postmenopausal women (United Kingdom). Cancer Causes Control 2001;12:47-59.
17. Moran C, Garcia-Hernandez E, Cortes MA, Calzada L, Salazar L, Bermudez JA. Estradiol and progesterone endometrial receptors and body fat distribu tion in obese women. Gynecol Obstet Invest 1996; 42:117-9.
18. Garland CF, Garland FC, Gorham ED, Lipkin M, Newmark H, Mohr SB, et al. The role of vitamin D in cancer prevention. Am J Public Health 2006;96:252-61.
19. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266-81.
20. Jiang F, Li P, Fornace AJ Jr. Nicosia SV, Bai W. G2/M arrest by 1,25-dihydroxyvitamin D3 in ovarian cancer cells mediated through the induction of GADD45 via an exonic enhancer. J Biol Chem 2003;278:48030-40.
21. Shen Z, Zhang X, Tang J, Kasiappan R, Jinwal U , Li P, et al. The coupling of epidermal growth factor receptor down regulation by 1alpha,25-dihydroxyvitamin D3 to the hormone-induced cell cycle arrest at the G1-S checkpoint in ovarian cancer cells. Mol Cell Endocrinol 2011; 338:58-67.
22. Zhang X, Nicosia SV, Bai W. Vitamin D receptor is a novel drug target for ovarian cancer treatment. Curr Cancer Drug Targets 2006;6: 229-44.
23. Zhang X, Li P, Bao J, Nicosia SV, Wang H, Enkemann SA, et al. Suppression of death receptor-mediated apoptosis by 1,25-dihydroxyvitamin D3 revealed by microarray analysis. J Biol Chem 2005; 280:35458-68.
24. Zhang X, Jiang F, Li P, Li C, Ma Q, Nicosia SV, et al., Growth suppression of ovarian cancer xenografts in nude mice by vitamin D analogue EB1089, Clin Cancer Res, 2005, 11, 323-8.
25. Jiang F, Bao J, Li P, Nicosia SV, Bai W. Induction of ovarian cancer cell apoptosis by 1,25-dihydroxyvitamin D3 through the down-regulation of telomerase. J Biol Chem 2004;279:53213-21.
26. Kasiappan R, Shen Z, Tse AK, Jinwal U, Tang J, Lungchukiet P, et al. 1,25-Dihydroxyvitamin D3 suppresses telomerase expression and human cancer growth through microRNA-498. J Biol Chem 2012;287: 41297-309.
27. Bao J, Cao C, Zhang X, Jiang F, Nicosia SV, Bai W. Suppression of beta-amyloid precursor protein signaling into the nucleus by estrogens mediated through complex formation between the estroge n receptor and Fe65. Mol Cell Biol 2007;27:1321-33.
28. Baldwin WS, Curtis SW, Cauthen CA, Risinger JI, Korach KS, Barrett JC. BG-1 ovarian cell line: an alternative model for examining estrogen-dependent growth in vitro. In Vitro Cell Dev Biol Anim 1998;34:649-54.
29. Pinelli DM, Drake J, Williams MC, Cavanagh D, Becker JL. Hormonal modulation of Ishikawa cells during three-dimensional growth in vitro. J Soc Gynecol Investig 1998;5: 217-23.
30. Sakai W, Swisher EM, Jacquemont C, Chandramohan KV, Couch FJ, Langdon SP, et al. Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. C ancer Res 2009;69:6381-6.
31. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
32. Kyo S, Takakura M, Kanaya T, Zhuo W, Fujimoto K, Nishio Y, et al. Estrogen activates telomerase. Cancer Res 1999;59:5917-21.
33. Kimura A, Ohmichi M, Ka wagoe J, Kyo S, Mabuchi S, Takahashi T, et al. Induction of hTERT expression and phosphorylation by estrogen via Akt cascade in human ovarian cancer cell lines. Oncogene 2004;23:4505-15.
34. Misiti S, Nanni S, Fontemaggi G, Cong YS, Wen J, Hirte HW, et al. Induction of hTERT expression and telomerase activity by estrogens in human ovary epithelium cells. Mol Cell Biol 2000;20: 3764-71.
35. Zhou C, Steplowski TA, Dickens HK, Malloy KM, Gehrig PA, Boggess JF, et al. Estrogen induction of telomerase activity through regulation of the mitogen-activated protein kinase (MAPK) dependent pathway in hum an endometrial cancer cells. PLoS ONE 2013;8:e55730.
36. Lonard DM, Nawaz Z, Smith CL, O'Malley BW. The 26S proteasome is required for estrogen receptor-alpha and coactivator turnover and for ef ficient estrogen receptor-alpha transactivation. Mol Cell 2000;5: 939-48.
37. Frederich RC, Hamann A, Anderson S, Lollmann B, Lowell BB, Flier JS. Leptin levels reflect body lipid content in mice: evidence for dietinduced resistance to leptin action. Nat Med 1995;1:1311-4.
38. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
39. Swami S, Krishnan AV, Feldman D. 1alpha,25-Dihydroxyvitamin D3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells. Clin Cancer Res 2000;6: 3371-9.
40. Demirpence E, Balaguer P, Trousse F, Nicolas JC, Pons M, Gagne D. Antiestrogenic effects of all-trans-retinoic acid and 1,25-dihydroxyvitamin D3 in breast cancer cells occur at the estrogen respon se element level but through different molecular mechanisms. Cancer Res 1994;54:1458-64.
41. Nelson ER, Wardell SE, Jasper JS, Park S, Suchindran S, Howe MK, et al. 27-Hydroxycholeste rol links hypercholesterolemia and breast cancer pathophysiology. Science 2013;342:1094-8.
42. Ren H, Zhao T, Wang X, Gao C, Wang J, Yu M, et al. Leptin upregulates telomerase activity and transcription of human telomerase reverse transcriptase in MCF-7 breast cancer cells. Biochem Biophys Res Co mmun 2010;394:59-63.
43. Stefanou N, Papanikolaou V, Furukawa Y, Nakamura Y, Tsezou A. Leptin as a critical regulator of hepatocellular carcinoma development through modulation of human telomeras e reverse transcriptase. BMC Cancer 2010;10:442.
44. Leitzmann MF, Koebnick C, Danforth KN, Brinton LA, Moore SC, Hollenbeck AR, et al. Body mass index and risk of ovarian cancer. Cancer 2009;115:812-22.
45. Schouten LJ, Rivera C, Hunter DJ, Spiegelman D, Adami HO, Arslan A, et al., Height, body mass index, and ovarian cancer: a pooled analysis of 12 cohort studie s, Cancer Epidemiol Biomarkers Prev, 2008, 17, 902-12.
46. Olsen CM, Green AC, Whiteman DC, Sadeghi S, Kolahdooz F, Web b PM. Obesity and the risk of epithelial ovarian cancer: a systematic review and meta-analysis. Eur J Cancer 2007;43:690-709.
47. Anderson GL, Judd HL, Kaunitz AM, Barad DH, Beresford SA, Pettinger M, et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA 2003;290:1739-48.
48. Yang HP, Anderson WF, Rosenberg PS, Trabert B, Gierach GL, Wentzensen N, et al. Ovarian cancer incidence trends in relation to changing patterns of menopausal hormone therapy use in the United States. J Clin Oncol 2013;31: 2146-51.
49. Zheng W, Danforth KN, Tworoger SS, Goodman MT, Arslan AA, Patel AV, et al. Circulating 25-hydroxyvitamin D and risk of epithelial ovarian cancer: Cohort Consortium Vitamin D Pooling Pro ject of Rarer Cancers. Am J Epidemiol 2010;172:70-80.
50. Lagunova Z, Porojnicu AC, Grant WB, Bruland O, Moan JE. Obesity and increased risk of cancer: does decrease of serum 25-hydroxyvitam in D level with increasing body mass index explain some of the association? Mol Nutr Food Res 2010;54:1127-33.